Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients
NCT ID: NCT03839251
Last Updated: 2021-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
82 participants
INTERVENTIONAL
2018-06-01
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect on Cognitive Function of a Treatment With Aripiprazole
NCT00329810
Efficacy and Safety of Aripiprazole in First Episode Psychosis
NCT01026584
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
NCT00292409
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
NCT00237939
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
NCT00325689
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
abilify maintena
aripiprazole 400mg or 300mg, IM, Once a month
abilify maintena
aripiprazole 400mg or 300mg, IM, Once a month
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
abilify maintena
aripiprazole 400mg or 300mg, IM, Once a month
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* men and women aged 19 and under 60
* a person who is being given an atypical antipsychotic.
* Patients should be able to reasonably cooperate with the questionnaire to be used for the study
* a person who fully understands the purpose of the study and signs the consent
* stable outpatient before screening without changing the volume of antipsychotics for at least two weeks
Exclusion Criteria
* A fertile woman who is currently pregnant or breastfeeding, or who is either unwilling or unable to use acceptable contraception until the clinical trial is complete.
* a person suffering from severe drug allergies or complex and severe drug reactions
* Patients who have taken clozapine in the last 60 days
* subjects showing significant risk of suicide or significant risk of violent behavior based on past history or investigator's judgment
19 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young Chul Chung
Professor of Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young-chul Chung, MD
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, Inje University Haeundae Paik Hospital
Busan, , South Korea
Department of Psychiatry, Kyungpook National University Hospital
Daegu, , South Korea
Department of Psychiatry, Yeungnam University Medical Center
Daegu, , South Korea
Department of Psychiatry, Chonnam National University Medical School
Gwangju, , South Korea
Department of Psychiatry, Chonbuk National University Hospital
Jeonju, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CUH 2018-02-011-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.